Ovarian Cancer Clinical Trial
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Summary
stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy
Full Description
The objective of this study is to prove that treatment with primary cytoreductive surgery in combination with HIPEC (treatment arm) improves outcome compared to primary cytoreductive surgery without HIPEC (standard arm) with acceptable morbidity, in patients with FIGO stage III epithelial ovarian cancer who are eligible for primary cytoreductive surgery with no residual disease, or residual disease up to 2.5 mm.
Eligibility Criteria
Inclusion Criteria:
candidate for primary CRS
histological or cytological proven FIGO stage III primary epithelial ovarian, fallopian tube, or extra-ovarian cancer
Exclusion Criteria:
history of previous malignancies within 5 years prior to inclusion
FIGO stage IV disease
complete primary cytoreduction is impossible
prior treatment for the current malignancy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 2 Locations for this study
New York New York, 10065, United States More Info
Principal Investigator
Copenhagen , , Denmark More Info
Principal Investigator
Bordeaux , , France More Info
Principal Investigator
Montpellier , , France More Info
Principal Investigator
Nantes , , France More Info
Principal Investigator
Toulouse , , France More Info
Principal Investigator
Dublin , , Ireland More Info
Principal Investigator
Bologna , , Italy More Info
Principal Investigator
Amsterdam Noord-Holland, 1066C, Netherlands More Info
Principal Investigator
Amsterdam , , Netherlands
Eindhoven , , Netherlands
Enschede , , Netherlands
Groningen , , Netherlands
Leiden , , Netherlands
Maastricht , , Netherlands
Nijmegen , , Netherlands
Rotterdam , , Netherlands
How clear is this clinincal trial information?